| 製品名 | Linagliptin |
|---|---|
| CAS番号 | 668270-12-0 |
| 分子式 | C25H28N8O2 |
| 分子量 | 472.54 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 分析（HPLC） | ≥99.0% |
| 乾燥減量 | ≤0.5% |
| 焼失残渣 | ≤0.1% |
| 重金属 | 10 ppm以下 |
| 融点 | 196-202°C |
| 比回転 | [α]D20 = +50° to +56° (c=1, methanol) |
お困りですか？ 弊社チームまでお問い合わせください
Linagliptin is the DPP-4 inhibitor that doesn’t need a dose adjustment for kidney or liver function – and that’s a big deal for type 2 diabetes patients who often have comorbidities. Unlike many of its peers, it’s cleared primarily via bile and gut, so it’s a safer bet for long-term use in renally impaired patients. For formulators, that means a competitive edge in a crowded market: you can offer a once-daily, 5 mg tablet that works reliably without the monitoring headaches.
We supply linagliptin as a high-purity, crystalline API that meets or exceeds pharmacopoeial standards. Every batch is rigorously tested and shipped with a full COA, so you can move from development to production with confidence.
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese